Ardelyx (NASDAQ:ARDX) has been given a $12.00 target price by equities research analysts at Cantor Fitzgerald in a report released on Monday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 111.27% from the company’s current price.
Several other research firms have also recently weighed in on ARDX. Ladenburg Thalmann Financial Services cut their target price on shares of Ardelyx from $19.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, November 22nd. BidaskClub upgraded shares of Ardelyx from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Zacks Investment Research lowered shares of Ardelyx from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Leerink Swann reiterated an “outperform” rating and set a $13.00 price objective on shares of Ardelyx in a research report on Tuesday, October 17th. Finally, ValuEngine lowered shares of Ardelyx from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $12.93.
Ardelyx (NASDAQ:ARDX) traded down $0.47 on Monday, reaching $5.68. 481,000 shares of the company traded hands, compared to its average volume of 284,297. The stock has a market capitalization of $275.77, a PE ratio of -2.55 and a beta of 0.44. Ardelyx has a 52 week low of $4.05 and a 52 week high of $15.40.
ILLEGAL ACTIVITY NOTICE: “Cantor Fitzgerald Reiterates “$12.00” Price Target for Ardelyx (ARDX)” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/12/cantor-fitzgerald-reiterates-12-00-price-target-for-ardelyx-ardx.html.
Ardelyx Company Profile
Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.